The World Health Organization's ATC classification organizes medical drugs based on therapeutic properties, chemical composition, and anatomy. It helps make essential medicines readily available globally and is widely used in the pharmaceutical industry.
| Level | Code | Title | |
|---|---|---|---|
| 1 | R | Respiratory system | |
| 2 | R05 | Cough and cold preparations | |
| 3 | R05D | Cough suppressants, excl. combinations with expectorants | |
| 4 | R05DA | Opium alkaloids and derivatives | |
| 5 | R05DA08 | Pholcodine |
The DDD is the assumed average maintenance dose per day for a drug used for its main indication in adults. The DDD is a unit of measurement and does not necessarily reflect the recommended or Prescribed Daily Dose. Therapeutic doses for individual patients and patient groups will often differ from the DDD as they will be based on individual characteristics (such as age, weight, ethnic differences, type and severity of disease) and pharmacokinetic considerations.
| Route | Amount |
|---|---|
| ORAL - Oral | 50 mg |
| Active Ingredient | Description | |
|---|---|---|
| Pholcodine |
Pholcodine is an opioid that has been widely used for the treatment of non-productive cough in children and adults. Pholcodine is a cough suppressant with mild sedative but little analgesic activity. Additionally pholcodine is a marker for sensitization to neuromuscular blocking agents (NMBA) and is intended for use as a diagnostic tool in NMBA-induced anaphylaxis. |
Note the following: The list of brand names is continuously updated, and thus does not include the total of products circulating worldwide.
